You are here : Home > BAL Team > Publications of the team from 2006 to 2018

Publications of the team from 2006 to 2018

Published on 14 October 2020
2018 

Ferreira RR, Madeira FD, Alves GF, Chambela MD, Curvo EDV, Moreira AD, de Sa RA, Mendonca-Lima L, Cabello PH, Bailly S, Feige JJ, Araujo-Jorge TC, Saraiva RM and Waghabi MC
TGF-ß polymorphisms are a risk factor for Chagas disease.
Disease Markers, 2018: Article Number 4579198

Goumans MJ, Zwijsen A, Ten Dijke P and Bailly S
Bone morphogenetic proteins in vascular homeostasis and disease.
Cold Spring Harbor Perspectives in Biology, 2018, 10(2): a031989

Ouarné M, Bouvard C, Boneva G, Mallet C, Ribeiro J, Desroches-Castan A, Soleilhac E, Tillet E, Peyruchaud O and Bailly S
BMP9, but not BMP10, acts as a quiescence factor on tumor growth, vessel normalization and metastasis in a mouse model of breast cancer.
Journal of Experimental & Clinical Cancer Research, 2018, 37(1): 209

Tillet E, Ouarné M, Desroches-Castan A, Mallet C, Subileau M, Didier R, Lioutsko A, Belthier G, Feige JJ and Bailly S
A heterodimer formed by bone morphogenetic protein 9 (BMP9) and BMP10 provides most BMP biological activity in plasma.
Journal of Biological Chemistry, 2018, 93(28): 10963-10974


2017 


Arvin-Berod M, Desroches-Castan A, Bonte S, Brugière S, Couté Y, Guyon L, Feige JJ, Baussanne I and Demeunynck M
Indolizine-based scaffolds as efficient and versatile tools: Application to the synthesis of biotin-tagged antiangiogenic drugs.
ACS Omega, 2017, 2(12): 9221-9230

Goumans MJ, Zwijsen A, ten Dijke P and Bailly S
BMPs in vascular homeostasis and disease.
Cold Spring Harbor Perspectives in Biology, 2017

Guignabert C, Bailly S and Humbert M
Restoring BMPRII functions in pulmonary arterial hypertension: Opportunities, challenges and limitations.
Expert Opinion on Therapeutic Targets, 2017, 21(2): 181-190


2016 

Ferreira RR, de Souza EM, de Oliveira FL, Ferrao PM, Gomes LH, Mendonca-Lima L, Meuser-Batista M, Bailly S, Feige JJ, de Araujo-Jorge TC and Waghabi MC
Proteins involved on TGF-ß pathway are up-regulated during the acute phase of experimental Chagas disease.
Immunobiology, 2016, 221(5): 587-594

García de Vinuesa A, Abdelilah-Seyfried S, Knaus P, Zwijsen A and Bailly S
BMP signaling in vascular biology and dysfunction.
Cytokine Growth Factor Reviews, 2016, 27: 65-79


2015 


el Din FA, Patri S, Thoreau V, Rodriguez-Ballesteros M, Hamade E, Bailly S, Gilbert-Dussardier B, Abou Merhi R and Kitzis A
Functional and splicing defect analysis of 23 ACVRL1 mutations in a cohort of patients affected by hereditary hemorrhagic telangiectasia.
PLoS One, 2015, 10(7): e0132111

Ferrão PM, d'Avila-Levy CM, Araujo-Jorge TC, Degrave WM, Goncalves AD, Garzoni LR, Lima AP, Feige JJ, Bailly S, Mendonça-Lima L and Waghabi MC
Cruzipain activates latent TGF-ß from host cells during T. cruzi invasion.
PLoS One, 2015, 10(5): e0124832

Levet S, Ouarne M, Ciais D, Coutton C, Subileau M, Mallet C, Ricard N, Bidart M, Debillon T, Faravelli F, Rooryck C, Feige JJ, Tillet E and Bailly S
BMP9 and BMP10 are necessary for proper closure of the ductus arteriosus.
Proceedings of the National Academy of Sciences, 2015, 112(25): E3207-3215

Mallet C, Lamribet K, Giraud S, Dupuis-Girod S, Feige JJ, Bailly S and Tillet E
Functional analysis of endoglin mutations from hereditary hemorrhagic telangiectasia type 1 patients reveals different mechanisms for endoglin loss of function.
Human Molecular Genetics, 2015, 24(1): 1142-1154

Tillet E and Bailly S
Emerging roles of BMP9 and BMP10 in hereditary hemorrhagic telangiectasia.
Frontiers in Genetics, 2015, 5: n°456


2014 


Bailly S
BMP9, BMP10 and ALK1: An emerging vascular signalling pathway with therapeutic applications. In Molecular mechanisms of angiogenesis: From ontogenesis to oncogenesis. Feige J.J., Pagès G. & Soncin F. Eds, Springer, 2014, pp 99-119

Levet S, Ricard N, Ciais D, Subileau M, Mallet C, Feige JJ, Vittet D and Bailly S
Specificity and redundancy of BMP9 and BMP10 in postnatal angiogenesis and lymphangiogenesis.
Angiogenesis, 2014, 17(1): 293-294

Tillet E and Bailly S
Emerging roles of BMP9 and BMP10 in hereditary hemorrhagic telangiectasia.
Frontiers in Genetics, 2014, 5: n°456

Vittet D
Lymphatic collecting vessel maturation and valve morphogenesis.
Microvascular Research, 2014
, 96: 31-37


Vittet D, Brouillet S, Hoffmann P, Alfaidy N and Feige JJ
Cultures de cellules endothéliales. Applications à l’étude de l’angiogenèse In Culture de cellules animales, edited by Barlovatz-Meimon G and Ronot X, Editions Inserm, 2014


2013 


Levet S, Ciais D, Merdzhanova G, Mallet C, Zimmers TA, Lee SJ, Navarro FP, Texier I, Feige JJ, Bailly S and Vittet D
Bone morphogenetic protein 9 (BMP9) controls lymphatic vessel maturation and valve formation.
Blood, 2013, 122(4): 598-607


2012 


Araujo-Jorge TC, Waghabi MC, Bailly S and Feige JJ
The TGF-beta pathway as an emerging target for Chagas disease therapy.
Clinical Pharmacology & Therapeutics, 2012, 92(5): 613-621

Bidart M, Ricard N, Levet S, Samson M, Mallet C, David L, Subileau M, Tillet E, Feige JJ and Bailly S
BMP9 is produced by hepatocytes and circulates mainly in an active mature form complexed to its prodomain.
Cellular and Molecular Life Sciences, 2012, 69(2): 313-324
Erratum in: Cell Mol Life Sci, 2012, 69(3):485

Ciais D and Bailly S
BMPs go for apelin to regulate angiogenesis. Focus on "Inhibition of apelin expression by BMP signaling in endothelial cells".
American Journal of Physiology-Cell Physiology, 2012, 303(11): C1127-1128

Dupuis-Girod S, Ginon I, Saurin JC, Marion D, Guillot E, Decullier E, Roux A, Carette MF, Gilbert-Dussardier B, Hatron PY, Lacombe P, Lorcerie B, Rivière S, Corre R, Giraud S, Bailly S, Paintaud G, Ternant D, Valette PJ, Plauchu H and Faure F
Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output.
Journal of the American Medical Association, 2012, 307(9): 948-955

Liu F, Kang I, Park C, Chang LW, Wang W, Lee D, Lim DS, Vittet D, Nerbonne JM and Choi K
ER71 specifies Flk-1+ hemangiogenic mesoderm by inhibiting cardiac mesoderm and Wnt signaling.
Blood, 2012, 119(14): 3295-3305

de Oliveira FL, Araujo-Jorge TC, de Souza EM, de Oliveira GM, Degrave WM, Feige JJ, Bailly S and Waghabi MC
Oral administration of GW788388, an inhibitor of transforming growth factor beta signaling, prevents heart fibrosis in chagas disease.
PLoS Neglected Tropical Diseases, 2012, 6(6): e1696

Ricard N, Ciais D, Levet S, Subileau M, Mallet C, Zimmers TA, Lee SJ, Bidart M, Feige JJ and Bailly S
BMP9 and BMP10 are critical for postnatal retinal vascular remodeling.
Blood, 2012, 119(25): 6162-6171

Vittet D, Merdzhanova G, Prandini MH, Feige JJ and Bailly S
TGFss1 inhibits lymphatic endothelial cell differentiation from mouse embryonic stem cells.
Journal of Cellular Physiology, 2012, 227(11): 3593-3602


2010 


Bailly S, Dupuis-Girod S and Plauchu H
Rendu-Osler disease: Clinical and molecular update.
Médecine Sciences (Paris), 2010, 26(10): 855-860

Dupuis-Girod S, Bailly S and Plauchu H
Hereditary hemorrhagic telangiectasia (HHT): From molecular biology to patient care.
Journal of Thrombosis and Haemostasis, 2010, 8(7): 1447-1456

Ricard N, Bidart M, Mallet C, Lesca G, Giraud S, Prudent R, Feige JJ and Bailly S
Functional analysis of the BMP9 response of ALK1 mutants from HHT2 patients: a diagnostic tool for novel ACVRL1 mutations.
Blood, 2010, 116(9): 1604-1612


2009 


David L, Feige JJ and Bailly S
Emerging role of bone morphogenetic proteins in angiogenesis.
Cytokine Growth Factor Reviews, 2009, 20(3): 203-212

Waghabi MC, de Souza EM, de Oliveira GM, Keramidas M, Feige JJ, Araújo-Jorge TC and Bailly S
Pharmacological inhibition of transforming growth factor beta signalling decreases infection and prevents heart damage in acute chagas disease.
Antimicrobial Agents Chemotherapy, 2009, 53(11): 4694-4701


2008 


Araujo-Jorge TC, Waghabi MC, Soeiro MD, Keramidas M, Bailly S and Feige JJ
Pivotal role for TGF-ß in infectious heart disease: The case of Trypanosoma cruzi infection and consequent Chagasic myocardiopathy.
Cytokine and Growth Factor Reviews, 2008, 19(5-6): 405-413

Bailly S
HHT is not a TGFß disease.
Blood, 2008, 111(2); 478

David L, Mallet C, Keramidas M, Lamandé N, Gasc JM, Dupuis-Girod S, Plauchu H, Feige JJ and Bailly S
Bone morphogenetic protein-9 is a circulating vascular quiescence factor.
Circulation Research, 2008, 102(8): 914-922


2007 


David L, Mallet C, Mazerbourg S, Feige JJ and Bailly S
Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells.
Blood, 2007, 109(5): 1953-1961

David L, Mallet C, Vailhe B, Lamouille S, Feige JJ and Bailly S
Activin receptor-like kinase 1 inhibits human microvascular endothelial cell migration: Potential roles for JNK and ERK.
Journal of Cellular Physiology, 2007, 213(2): 484-489

Vittet D and Feige JJ
Lymphangiogenesis and tumor progression.
Bulletin du Cancer, 2007, 94(10): 881-886

Waghabi MC, Keramidas M, Calvet CM, Meuser M, Soeiro MD, Mendonca-Lima L, Araujo-Jorge TC, Feige JJ and Bailly S
SB-431542, a transforming growth factor ß inhibitor, impairs Trypannosoma cruzi infection in cardiomyocytes and parasite cycle completion.
Antimicrobial Agents and Chemotheraphy, 2007, 51(8): 2905-2910


2006 


Mallet C, Vittet D, Feige JJ and Bailly S
TGFß1 induces vasculogenesis and inhibits angiogenic sprouting in an embryonic stem cell differentiation model: Respective contribution of ALK1 and ALK5.
Stem Cells, 2006, 24(11): 2420-2427